Genelux Co. (NASDAQ:GNLX) General Counsel Sean Ryder Sells 5,496 Shares

Genelux Co. (NASDAQ:GNLX) General Counsel Sean Ryder sold 5,496 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $2.12, for a total value of $11,651.52. Following the completion of the sale, the general counsel now directly owns 19,388 shares of the company’s stock, valued at approximately $41,102.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Genelux Stock Up 14.7 %

Shares of Genelux stock opened at $2.49 on Thursday. The company has a market cap of $85.53 million, a PE ratio of -2.57 and a beta of -1.58. The business has a 50 day moving average of $2.85 and a 200 day moving average of $6.33. Genelux Co. has a 52 week low of $1.71 and a 52 week high of $35.15.

Genelux (NASDAQ:GNLX) last announced its earnings results on Thursday, May 9th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.08). The company had revenue of $0.01 million during the quarter. On average, research analysts anticipate that Genelux Co. will post -0.86 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on GNLX. Benchmark lowered their price objective on Genelux from $30.00 to $25.00 and set a “speculative buy” rating for the company in a research report on Friday, May 31st. HC Wainwright reiterated a “buy” rating and issued a $32.00 price objective on shares of Genelux in a research report on Monday, May 13th.

Hedge Funds Weigh In On Genelux

A number of hedge funds and other institutional investors have recently made changes to their positions in GNLX. Vanguard Group Inc. raised its holdings in shares of Genelux by 1,660.1% during the third quarter. Vanguard Group Inc. now owns 980,993 shares of the company’s stock valued at $24,025,000 after acquiring an additional 925,258 shares in the last quarter. Exchange Traded Concepts LLC grew its stake in Genelux by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 6,201 shares of the company’s stock worth $87,000 after purchasing an additional 1,573 shares during the period. Falcon Wealth Planning grew its stake in Genelux by 20.0% in the fourth quarter. Falcon Wealth Planning now owns 12,000 shares of the company’s stock worth $168,000 after purchasing an additional 2,000 shares during the period. KWB Wealth purchased a new stake in Genelux in the fourth quarter worth $327,000. Finally, Whittier Trust Co. of Nevada Inc. purchased a new stake in Genelux in the fourth quarter worth $100,000. Institutional investors own 37.33% of the company’s stock.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.